FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
News|Articles|September 16, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
- Volume 11
- Issue 10
FDA Issues Import Ban for Indian Drug Manufacturer
Author(s)Pharmaceutical Technology Editors
Polydrug Laboratories is issued a US import alert, following similar bans in Canada and Europe.
Advertisement
FDA has issued an import ban on Sept. 11, 2015 for products manufactured by Polydrug Laboratories at the company’s Ambernath Industrial Area manufacturing plant in Mumbai, India, due to problems with good manufacturing practices for human and animal drugs.
The company manufactures anti-hypertensive, anti-fungal, anti-microbial, and muscle relaxant drugs, and distributes products in Mexico, China, Korea, Russia,Taiwan, Singapore, and Ukraine, according to information posted on the
Source:
Articles in this issue
about 11 years ago
Cost Inhibits CMO Adoption of Single-Use Equipmentabout 11 years ago
Low Temperature Needed for Complex Drug Candidatesabout 11 years ago
FDA Plans Pilot Projects for Drug Supply Chain Security Actabout 11 years ago
Vetter Embarks on 300-Million Euro Manufacturing Expansionabout 11 years ago
Sterigenics International Adds Capacityabout 11 years ago
Tecnandina’s Ecuador Facility Receives ANVISA Certificationabout 11 years ago
Hovione Expands Drug Substance Manufacturingabout 11 years ago
Piramal Introduces Proof of Concept Service for Next Wave of ADC Growthabout 11 years ago
Patheon Unveils New Brand Identityabout 11 years ago
FDA Releases Guidance on Generic-Drug DevelopmentAdvertisement
Related to this article
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
Germany’s Medical Biotechnology Sector is Flourishing
5